Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $4.51M, compared with -$5.28M a year earlier. Trailing-twelve-month accounts receivables was -$2.71M. Over 3 fiscal years it compounded at +101.6% a year.
Context
- Accounts receivables amounted to 28.4% of revenue in FY2025, up 11.8 pp from a year earlier.
- Accounts receivables grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $4.51M or moves back toward the trailing-twelve-month quarterly average of -$676.27K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (12.66M) USD
- Year-over-year change
- -60.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.66M) | -60.8% |
| FY2024 | 2024-12-31 | (7.87M) | -8.3% |
| FY2023 | 2023-12-31 | (7.27M) | -370.5% |
| FY2022 | 2022-12-31 | (1.55M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 accounts receivables of $2.71M is the 2nd largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of -76.9% is the lowest of 7, against a peer median of +135.7%.
- Accounts receivables amounts to 5.3% of revenue for FENC, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.8M | +4000.1% | +39.1% | 47.4% | |
| LTM Mar 2026 | $2.71M | -76.9% | +101.6% | 5.3% | |
| LTM Mar 2026 | $1.5M | -42.4% | — | 84.7% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $405.95K | +181.5% | — | — |
| LTM Mar 2026 | $378K | -56.7% | -57.2% | 3.4% | |
| LTM Mar 2026 | $5K | +171.4% | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding FENC) | $0 | +135.7% | -9.0% | 1.7% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (10.27M) |
| Depreciation & Amortization | 16K | 149K | 287K | 959K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.01M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (138K) | (509K) | (8.17M) | (7.33M) | (15.09M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.66M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.3M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 1.42M |
| Other Working Capital | (138K) | 1.61M | 683K | (35K) | (2.55M) |
| Other Non-Cash Items | (769K) | 1.8M | 1.43M | 28.73M | 5.76M |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 20.17M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 33K | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (55K) | 753K | 1.72M | (439K) | (2.57M) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 22.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 10.15M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.